Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJan 24, 2026
DataAggregated Company Financials
Companies9
  • 7D-0.4%
  • 3M19.7%
  • 1Y29.0%
  • YTDn/a

In the last week, the Pharma industry is flat overall, with Galderma Group standing out by going down 5.8%. As for the the longer term, the industry is up 29% over the past 12 months. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 24 Jan 2026CHF 589.2bCHF 120.5bCHF 21.4b36.9x27.5x4.9x
Mon, 22 Dec 2025CHF 556.4bCHF 121.1bCHF 21.5b33.6x25.9x4.6x
Wed, 19 Nov 2025CHF 521.7bCHF 121.3bCHF 21.6b33.8x24.2x4.3x
Fri, 17 Oct 2025CHF 506.2bCHF 119.9bCHF 20.9b33.5x24.3x4.2x
Sun, 14 Sep 2025CHF 479.5bCHF 120.2bCHF 20.9b31.8x22.9x4x
Tue, 12 Aug 2025CHF 454.3bCHF 121.2bCHF 21.0b22.2x21.7x3.7x
Thu, 10 Jul 2025CHF 454.3bCHF 117.1bCHF 18.9b25x24.1x3.9x
Sat, 07 Jun 2025CHF 457.0bCHF 119.0bCHF 19.3b25.8x23.7x3.8x
Mon, 05 May 2025CHF 446.5bCHF 119.2bCHF 19.3b26.2x23.2x3.7x
Wed, 02 Apr 2025CHF 463.1bCHF 121.8bCHF 19.2b28.1x24.1x3.8x
Fri, 28 Feb 2025CHF 479.4bCHF 122.3bCHF 19.1b23.3x25.1x3.9x
Sun, 26 Jan 2025CHF 450.4bCHF 119.4bCHF 21.4b18.8x21.1x3.8x
Tue, 24 Dec 2024CHF 420.4bCHF 119.0bCHF 21.3b17.7x19.7x3.5x
Thu, 21 Nov 2024CHF 424.2bCHF 118.0bCHF 21.1b18.1x20.1x3.6x
Sat, 19 Oct 2024CHF 464.3bCHF 115.8bCHF 19.5b22x23.8x4x
Mon, 16 Sep 2024CHF 451.0bCHF 114.8bCHF 19.3b21.6x23.4x3.9x
Wed, 14 Aug 2024CHF 460.3bCHF 115.8bCHF 19.5b21.8x23.6x4x
Fri, 12 Jul 2024CHF 443.6bCHF 116.3bCHF 19.8b34.3x22.5x3.8x
Sun, 09 Jun 2024CHF 426.0bCHF 116.3bCHF 19.8b44.1x21.6x3.7x
Tue, 07 May 2024CHF 390.5bCHF 113.2bCHF 19.9b39.5x19.6x3.5x
Thu, 04 Apr 2024CHF 400.8bCHF 112.0bCHF 19.4b36.8x20.7x3.6x
Sat, 02 Mar 2024CHF 388.1bCHF 110.5bCHF 19.7b24.3x19.7x3.5x
Mon, 29 Jan 2024CHF 413.8bCHF 120.2bCHF 18.8b27x22.1x3.4x
Wed, 27 Dec 2023CHF 394.7bCHF 119.7bCHF 18.7b25x21.1x3.3x
Fri, 24 Nov 2023CHF 391.8bCHF 121.4bCHF 18.9b24.6x20.7x3.2x
Sun, 22 Oct 2023CHF 390.9bCHF 120.9bCHF 18.6b25.7x21.1x3.2x
Tue, 19 Sep 2023CHF 410.0bCHF 112.7bCHF 18.0b46.4x22.7x3.6x
Thu, 17 Aug 2023CHF 408.0bCHF 111.7bCHF 17.9b48.3x22.8x3.7x
Sat, 15 Jul 2023CHF 408.4bCHF 113.3bCHF 18.6b36.9x21.9x3.6x
Mon, 12 Jun 2023CHF 428.7bCHF 115.5bCHF 18.9b37.9x22.6x3.7x
Wed, 10 May 2023CHF 437.2bCHF 114.9bCHF 18.8b41x23.2x3.8x
Fri, 07 Apr 2023CHF 431.3bCHF 115.2bCHF 18.9b42.4x22.9x3.7x
Sun, 05 Mar 2023CHF 400.5bCHF 116.8bCHF 19.1b27.3x21x3.4x
Tue, 31 Jan 2023CHF 445.5bCHF 118.1bCHF 35.0b23.6x12.7x3.8x
Price to Earnings Ratio

12.7x


Total Market Cap: CHF 445.5bTotal Earnings: CHF 35.0bTotal Revenue: CHF 118.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.3x202420252026
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 27.4x which is higher than its 3-year average PE of 22.3x.
  • The 3-year average PS ratio of 3.7x is lower than the industry's current PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 15% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Pharma compare with similar industries?

CH Market-1.51%
Healthcare-0.33%
Pharma-0.36%
Pharma-0.36%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SDZ Sandoz GroupCHF 63.682.6%
+CHF 689.1m		48.5%PE153.3x
NOVN NovartisCHF 115.640.03%
+CHF 76.8m		28.1%PE19.6x
BIOV BioVersysCHF 26.0015.0%
+CHF 19.9m		n/aPS116.2x
COPN Cosmo PharmaceuticalsCHF 114.200.9%
+CHF 15.9m		75.2%PE32.7x
CURN Curatis HoldingCHF 16.801.2%
+CHF 1.0m		28.7%n/a

Latest News

SDZ
CHF 63.68
Sandoz Group
7D
2.6%
1Y
48.5%

SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks

Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.
GALD
CHF 149.80
Galderma Group
7D
-5.8%
1Y
36.5%

GALD: Raised Growth Outlook And L’Oréal Stake Increase Will Support Re Rating

Analysts have raised their blended price target range for Galderma Group to approximately CHF 195 to CHF 200 from about CHF 140 to CHF 165, citing updated fair value estimates, revised assumptions for revenue growth and profit margins, as well as a higher projected P/E multiple. Analyst Commentary Recent Street research points to a more constructive stance on Galderma Group, with several bullish analysts lifting their price targets into the CHF 140 to CHF 195 range.
NOVN
CHF 115.64
Novartis
7D
0.03%
1Y
28.1%
NWRN
CHF 21.50
Newron Pharmaceuticals
7D
-13.0%
1Y
128.0%
DESN
CHF 359.50
Dottikon ES Holding
7D
-0.8%
1Y
66.4%

Does Dottikon ES Holding (VTX:DESN) Deserve A Spot On Your Watchlist?

Jan 14
Does Dottikon ES Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
ADXN
CHF 0.055
Addex Therapeutics
7D
0.7%
1Y
-12.3%
COPN
CHF 114.20
Cosmo Pharmaceuticals
7D
0.9%
1Y
75.2%

COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended

Analysts have trimmed their price target for Cosmo Pharmaceuticals by roughly €0.46, reflecting slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple in their updated models. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream), following a prior positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).
ROG
CHF 348.10
Roche Holding
7D
-0.2%
1Y
26.6%

ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution

Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.
BIOV
CHF 26.00
BioVersys
7D
15.0%
1Y
n/a
CURN
CHF 16.80
Curatis Holding
7D
1.2%
1Y
28.7%